- Home >
- Life Sciences >
- Pharmaceutical >
- Pathology >
Pathology Industry Analysis and Statistics (since 2008 - p3)
All premium reports for Pathology Industry Analysis and Statistics (since 2008 - p3)
61-90 of 214 Premium Reports from 18 Publishers
Immtech Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Immtech Pharmaceuticals, Inc. - Financial and Strategic Analysis ReviewSummaryImmtech Pharmaceuticals, Inc. mainly focuses on the global opportunities in the healthcare sector. It is engaged in discovery and development of therapies for the treatment of infectious diseases. The company mainly carrie ...
Industries : Pathology
Cardiome Pharma Corp - Financial and Strategic Analysis Review
- $ 125
- April 2009
Cardiome Pharma Corp - Financial and Strategic Analysis ReviewSummaryCardiome Pharma Corp. (Cardiome) is a drug research and development company that focuses on developing products for the treatment and prevention of cardiovascular diseases. The company is headquartered in Vancouver, British Columbi ...
Industries : Pathology
Achillion Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Achillion Pharmaceuticals, Inc. - Financial and Strategic Analysis ReviewSummaryAchillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company engaged in the development and marketing of innovative drug products for the infectious disease market. It develops clinical compounds and pre cl ...
Industries : Pathology
Forest Laboratories, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Forest Laboratories, Inc. - Financial and Strategic Analysis ReviewSummaryForest Laboratories, Inc. (Forest Lab) is a U.S. based pharmaceutical company. It is engaged in the development, manufacturing and selling of both branded and generic forms of ethical drug products and over-the-counter product ...
Novavax, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Novavax, Inc. - Financial and Strategic Analysis ReviewSummaryNovavax is a development stage biotechnology company engaged in discovery of new vaccines across the broad range of infectious diseases. The company is developing the drugs with the help of advanced proprietary virus-like particle (VLP) t ...
Industries : Pathology
Salix Pharmaceuticals, Ltd. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Salix Pharmaceuticals, Ltd. - Financial and Strategic Analysis ReviewSummarySalix Pharmaceuticals (Salix) is a pharmaceutical company. It is principally engaged in the developing and marketing of prescription drugs, for the treatment of gastrointestinal diseases. The company carries out its operati ...
Industries : Pathology
Santarus, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Santarus, Inc. - Financial and Strategic Analysis ReviewSummarySantarus, Inc. (Santarus) is a specialty pharmaceutical company that is principally engaged in development, production and commercialization of products for gastrointestinal diseases and disorders. Zegerid, is the approved product of th ...
Industries : Pathology
ViroPharma Incorporated - Financial and Strategic Analysis Review
- $ 125
- April 2009
ViroPharma Incorporated - Financial and Strategic Analysis ReviewSummaryViroPharma Incorporated (ViroPharma) is engaged in the development and marketing of pharmaceutical products for infectious diseases. The company?s products are used by physician specialists in hospital settings. ViroPharma has o ...
Industries : Pathology
CV Therapeutics, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
CV Therapeutics, Inc. - Financial and Strategic Analysis ReviewSummaryCV Therapeutics, Inc. (CV Therapeutics) is engaged in the research, development, manufacture, and sale of new small molecule drugs, which are used for the treatment of cardiovascular diseases. The company uses new technologies in ...
Industries : Pathology
Crucell N.V. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Crucell N.V. - Financial and Strategic Analysis ReviewSummaryCrucell N.V. (Crucell) is a biopharmaceutical company. It is focused on developing, producing and marketing products that combat infectious diseases. The company develops products that address unmet medical needs, particularly in the field ...
Industries : Pathology
China Cardiovascular Devices Market Analysis & Forecasts to 2015
- $ 3 500
- April 2009
China Cardiovascular Devices Market Analysis & Forecasts to 2015SummaryThis report is an essential source for in-depth information and data relating to the China cardiovascular devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company sha ...
Industries : Pathology
Stakeholder Opinions: Urinary Tract Infections Growing resistance rates bring opportunities for both new and old drugs
- $ 5 795
- April 2009
IntroductionUrinary tract infections (UTIs) include infections of the kidneys, ureters, and bladder. Escherichia coli is the major UTI pathogen, with emerging extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly difficult to treat. Bacterial resistance to the most commonly ...
Industries : Pathology
Diabetes, Metabolic Syndrome and Cardiovascular Disease
- $ 3 400
- April 2009
- 265 pages
There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked t ...
Industries : Pharmaceutical, Pathology
Blood Glucose Testing and Diabetes Management
- $ 3 400
- April 2009
- 366 pages
There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked t ...
Industries : Diagnostics, Medical Equipment and Supply, Pathology | Countries : USA, Japan, France
Stakeholder Opinions: Commercial strategies in cardiovascular and metabolic diseases successful market positioning at company and brand level becomes paramount
- $ 3 800
- April 2009
IntroductionDatamonitor expects commercial strategies in the cardiovascular and metabolic markets to become increasingly important as the markets mature. The report details strategies used by pharmaceutical companies to capture market share, to differentiate brands from the competition, for revenue ...
Industries : Pathology
Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth
- $ 3 500
- March 2009
- 51 pages
Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive GrowthSummaryGlobalData?s ?Global Self Monitoring Blood Glucose (SMBG) Market: Increasing Adoption to Drive Growth? report is an essential source of data and analysis on the Self Monitoring Blood Glucose (SMBG) market w ...
Industries : Diagnostics, Pathology
AstraZeneca plc - Company Profile, Executives, Financials and Condensed Data
- $ 0
- March 2009
- 5 pages
This report provides an in-depth company profile for AstraZeneca plc ranked 265 in the 2008 Fortune Global 500. All data is gathered from primary source. Reports are available in easily accessible PDF format and data is consistently presented. Data is regularly tracked and enhanced to ensure data on ...
Industries : Pathology
Vectura Group plc - SWOT Analysis
- $ 125
- March 2009
Datamonitor's Vectura Group plc - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company?s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Vec ...
Industries : Pathology
Antithrombotics Market Forecast
- $ 15 200
- March 2009
IntroductionThe antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and ...
Industries : Pathology
Blood and Lymphatic System Anemia
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Anemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of anemia drugs by company and by stage as well as a summary of the latest news and developments in this area.Scope of the repo ...
Industries : Pathology
Blood and Lymphatic System Dyslipidemia
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Dyslipidemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of dyslipidemia drugs by company and by stage as well as a summary of the latest news and developments in this area.Scope ...
Industries : Pathology
Blood and Lymphatic System Electrolyte Deficiencies
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Electrolyte Deficiencies contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of electrolyte deficiencies drugs by company and by stage as well as a summary of the latest news and develop ...
Industries : Pathology
Blood and Lymphatic System Hemophilia or Blood Coagulation Disorders
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Hemophilia or Blood Coagulation Disorders contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of hemophilia or blood coagulation disorders drugs by company and by stage as well as a summ ...
Industries : Pathology
Blood and Lymphatic System Hemorrhage
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Hemorrhage contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of hemorrhage drugs by company and by stage as well as a summary of the latest news and developments in this area.Scope of ...
Industries : Pathology
Blood and Lymphatic System Hyperlipemia
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Hyperlipemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of hyperlipemia drugs by company and by stage as well as a summary of the latest news and developments in this area.Scope ...
Industries : Pathology
Blood and Lymphatic System Myelodysplastic Syndrome
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Myelodysplastic Syndrome contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of myelodysplastic syndrome drugs by company and by stage as well as a summary of the latest news and develop ...
Industries : Pathology
Blood and Lymphatic System Thrombocytopenia or Idiopathic Thrombocytopenic Purpura
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Thrombocytopenia or Idiopathic Thrombocytopenic Purpura contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of thrombocytopenia or idiopathic thrombocytopenic purpura drugs by company an ...
Industries : Pathology
Blood and Lymphatic System Thromboembolism
- $ 1 495
- March 2009
Life Science Analytics', Blood and Lymphatic System Thromboembolism contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of thromboembolism drugs by company and by stage as well as a summary of the latest news and developments in this area ...
Industries : Pathology
Cardiovascular and Circulatory System Acute Coronary Syndromes
- $ 1 495
- March 2009
Life Science Analytics', Cardiovascular and Circulatory System Acute Coronary Syndromes contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of acute coronary syndromes drugs by company and by stage as well as a summary of the latest news ...
Industries : Pathology
Cardiovascular and Circulatory System Angina
- $ 1 495
- March 2009
Life Science Analytics', Cardiovascular and Circulatory System Angina contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of angina drugs by company and by stage as well as a summary of the latest news and developments in this area.Scope ...
Industries : Pathology
reportlinker.com © Copyright 2009. All rights reserved